PODOFILOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PODOFILOX (PODOFILOX).
Podofilox is a microtubule-disrupting agent that binds to tubulin, inhibiting microtubule polymerization and thereby arresting cell division in metaphase. It also induces necrosis of epithelial cells by interfering with cellular metabolism and DNA synthesis.
| Metabolism | Podofilox undergoes hepatic metabolism primarily via cytochrome P450 enzymes, including CYP3A4. It is also metabolized by esterases and conjugation reactions. |
| Excretion | Primarily renal excretion of metabolites; approximately 70-80% excreted in urine as unchanged drug and glucuronide conjugates, with about 10-20% in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is 2-4 hours in patients with normal renal function; may be prolonged in hepatic impairment or severe renal dysfunction. |
| Protein binding | Approximately 85% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution primarily within total body water and minimal tissue binding. |
| Bioavailability | Topical: Approximately 1-2% systemic absorption when applied to intact skin; absorption increases with mucosal application or broken skin (up to 10-20%). |
| Onset of Action | Topical: Clinical effect (resolution of lesions) typically begins within 2-4 weeks of treatment initiation, with maximum effect by 6-8 weeks. |
| Duration of Action | Duration of action is not well-defined; treatment course is typically 8-12 weeks, with effects persisting for several weeks after discontinuation. Retreatment may be needed for persistence or recurrence. |
Topical 0.5% solution or gel applied to external genital/perianal warts twice daily for 3 consecutive days, followed by 4 days without treatment; repeat weekly for up to 4 cycles. Maximum application area: 10 cm². Maximum volume per session: 0.5 mL.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years; use not recommended. |
| Geriatric use | No specific dose adjustments; use with caution due to potential for increased skin sensitivity or reduced renal/hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PODOFILOX (PODOFILOX).
| Breastfeeding | No data on excretion into human breast milk. The low systemic absorption after topical use suggests minimal risk, but caution is advised. M/P ratio: Unknown. The manufacturer recommends discontinuing nursing or the drug due to potential for serious adverse reactions in the infant. |
| Teratogenic Risk | FDA Pregnancy Category C. Based on animal studies, podofilox is embryotoxic and teratogenic. In humans, systemic absorption after topical application is minimal, but the drug should be avoided in pregnancy due to potential fetal harm. Risk cannot be ruled out; use only if benefit outweighs risk. Trimesters: First trimester: Avoid; potential teratogenic effects. Second and third trimesters: Limited data; avoid unless necessary. |
■ FDA Black Box Warning
None
| Serious Effects |
Absolute: Hypersensitivity to podofilox or any component of the formulation. Relative: Pregnancy (Category C; not recommended unless potential benefit outweighs risk), breastfeeding, children under 18 years of age (safety not established), application to mucosal surfaces or areas with compromised skin integrity.
| Precautions | Avoid contact with eyes and mucous membranes. Do not use on bleeding warts or open wounds. Limit application area to ≤10 cm² and total dose to ≤0.5 mL per day to reduce systemic absorption. Neurotoxicity and bone marrow suppression may occur with excessive use or accidental ingestion. Discontinue if severe local irritation or systemic symptoms develop. |
Loading safety data…
| Fetal Monitoring | Monitor for local adverse reactions (burning, pain, inflammation) at application site. No specific fetal monitoring required, but assess fetal well-being if used inadvertently. Periodic liver function tests and complete blood counts are not routinely indicated with topical use. |
| Fertility Effects | Animal studies have not shown impaired fertility. Human data are lacking. No known effect on reproductive function with topical use. |